<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00489905</url>
  </required_header>
  <id_info>
    <org_study_id>CRE-2005.137-T</org_study_id>
    <secondary_id>HARECCTR0500010</secondary_id>
    <nct_id>NCT00489905</nct_id>
  </id_info>
  <brief_title>Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer</brief_title>
  <official_title>Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Authority, Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Authority, Hong Kong</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of zoledronic acid on bone mineral density
      in prostatic cancer patients currently receiving androgen deprivation therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone mineral density of lumber spine</measure>
    <time_frame>12 months after administration of zolderonic acid</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone mineral density of femoral neck</measure>
    <time_frame>12 months after administration of zolderonic acid</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum creatinine, calcium, phosphate and alkaline phosphatase</measure>
    <time_frame>From time of enrollment to 3 months after the last intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in creatinine clearance</measure>
    <time_frame>From time of enrollment to 3 months after the last intervention</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <condition>Bone Density</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolderonic acid (Zometa)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prostate cancer patients aged between 50-80 who is having or will have ADT. Baseline
             BMD in between -2 standard deviation (SD) and mean of that among young adults.

        Exclusion Criteria:

          -  Patients with renal or liver problems, on calcium or other bisphosphonate therapy
             within six months before enrolling into the study.

        Patients who have:

          -  Serum creatinine levels &gt;212 Âµmol/L (2.4 mg/dL).

          -  Creatinine clearance &lt;50 ml/min.

          -  WBC &lt;4.0x109/L, Hgb &lt;10 g/dL, platelets &lt;140x109/L. Patients with known
             hypersensitivity to bisphosphonates. Patients with history of diseases with influence
             on bone metabolism, such as Page's disease of bone, primary hyperparathyroidism or
             osteoporosis.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Chi Fai Ng, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery, Division of Urology, The Chinese University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Urology, Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ekg.org.hk/HAREC-CTR/RegistryDisplay2.jsp?HARECID=HARECCTR0500010</url>
    <description>HAREC Clinical Trial Registry</description>
  </link>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2007</study_first_submitted>
  <study_first_submitted_qc>June 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2007</study_first_posted>
  <last_update_submitted>October 22, 2013</last_update_submitted>
  <last_update_submitted_qc>October 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2013</last_update_posted>
  <keyword>prostate cancer</keyword>
  <keyword>bone mineral density</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Zoledronic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

